SustainabilityESG Data

Environmental

INPUT

Items Units FY2021 FY2022 FY2023 FY2024 FY2025
Energy consumption
Electricity Consumption Thousand kwh 90,196 115,948 118,424 141,007 141,115
In-house Power Generation (Renewable) Thousand kwh 0 0 0 39 51
In-house Power Generation (Non-renewable) Thousand kwh 2,239 1,465 852 1,375 2,156
Purchased Electricity (PPA) Thousand kwh 96 285 269 750 730
Purchased Electricity (CO2-free / Carbon-free) Thousand kwh - - 8,033 15,467 20,410
Purchased Electricity (Other than the above) Thousand kwh 87,861 114,198 109,271 123,376 117,768
Electricity Certificate / Non-Fossil Certificate (NFC) Usage Thousand kwh - - - - 36,496
Other Energy
Kerosene kl 1,991 1,728 2,088 1,615 1,616
Heavy oil (A type) kl 736 511 308 318 8
Diesel Oil (Excluding vehicle use) kl 0.09 0 0.17 0.14 0.08
Gasoline (Excluding vehicle use) kl 0 0 0 0.09 0.08
LPG t 1 2,187 1,274 1,308 1,296
LNG t 0 0 0 635 720
City Gas Thousand m3 3,984 4,971 4,752 4,429 4,844
Steam (Non-industrial use) GJ 56,700 55,484 56,237 60,734 64,209
Diesel Oil (Vehicle use) kl - - - - 3.36
Gasoline (Vehicle use) kl - - - - 0.56
Total Energy Consumption
Crude oil equivalent kl 30,452 40,628 36,955 42,216 47,227
Per unitCrude oil equivalent divided by production volume (unit: hundred million tablets) - 115 141 132 145 162
Water
Total Water Withdrawal Thousand m3 360 357 348 447 457
Per unitTotal Water Withdrawal divided by production volume (unit: hundred million tabletss) - 1.36 1.24 1.25 1.53 1.57
Tap Water Thousand m3 325 307 307 392 417
Industrial Water Thousand m3 35 50 41 50 39
Desalinated Water Thousand m3 0.01 0.01 0.02 0.01 0.02
Well Water Thousand m3 0 0 0 4 1

* Up to FY2021: Includes only Sawai Pharmaceutical and Kaken Shoyaku (excluding water data).
* From FY2022 onward: Includes Trust Pharmatech (excluding water data).
* From FY2024 onward: Covers the entire Sawai Group.
* From FY2025 onward: Includes energy consumption for vehicle use that has received third-party verification.

OUTPUT

Items Units FY2021 FY2022 FY2023 FY2024 FY2025
Greenhouse Gases (GHG) *Includes fluorocarbons (Details shown separately)
Scope 1
Energy-related / Energy-derived kt-CO2e 15.2 22.7 18.7 19.4 20.4
Non-energy-related (HFCs, HCFCs, etc.) kt-CO2e - - - - 0.7
Scope 2 (Location-based)
After offsetting with Non-Fossil Certificates, etc. kt-CO2e 41.4 51.9 50.3 54.7 36.7
Scope 1 + Scope 2 (Location-based)
After offsetting with Non-Fossil Certificates, etc. kt-CO2e 56.6 74.6 69.1 74.1 57.8
Per unit[Scope 1+2 (Location-based) divided by production volume (unit: billion tablets)] - 2.1 2.6 2.5 2.5 2.0
Scope 2 (Market-based)
After offsetting with Non-Fossil Certificates, etc. kt-CO2e 38.1 46.5 50.3 55.0 38.0
Scope 1 + Scope 2 (Market-based)
After offsetting with Non-Fossil Certificates, etc. kt-CO2e 53.3 67.9 69.1 74.4 59.1
Per unit[Scope 1+2 (Market-based) divided by production volume (unit: billion tablets)] - 2.0 2.4 2.5 2.6 2.0
Scope 3 kt-CO2e 222.5 256.6 231.2 354.3 275.5
1. Purchased goods and services kt-CO2e 188.9 198.7 198.4 217.7 221.0
2. Capital goods kt-CO2e 12.2 36.0 10.8 113.6 32.0
3. Fuel-and energy-related activities kt-CO2e 7.8 8.1 8.3 10.5 10.2
4. Upstream transportation and distribution kt-CO2e 8.8 7.9 7.3 6.0 5.5
5. Waste generated in operations kt-CO2e 1.0 1.1 1.1 1.2 1.2
6. Business travel kt-CO2e 0.2 0.2 0.2 0.3 0.3
7. Employee commuting kt-CO2e 0.9 1.1 1.1 1.5 1.7
8. Upstream leased assets kt-CO2e N/A N/A N/A N/A N/A
9. Downstream transportation and distribution kt-CO2e 1.9 2.4 2.9 3.1 2.9
10. Processing of sold products kt-CO2e N/A N/A N/A N/A N/A
11. Use of sold products kt-CO2e N/A N/A N/A N/A N/A
12. End-of-life treatment of sold products kt-CO2e N/A N/A N/A N/A N/A
13. Downstream leased assets kt-CO2e N/A N/A N/A N/A N/A
14. Franchises kt-CO2e N/A N/A N/A N/A N/A
15. Investments kt-CO2e 0.8 1.1 1.1 0.5 0.7
Scope 1 + Scope 2 (Location-based) + Scope 3
After offsetting with Non-Fossil Certificates, etc. kt-CO2e 279.1 331.2 300.3 428.4 333.3
Scope 1 + Scope 2 (Market-based) + Scope 3
After offsetting with Non-Fossil Certificates, etc. kt-CO2e 275.8 324.5 300.3 428.7 334.6
Water
Total Water Discharge Thousand m3 353 330 324 420 430
Sewer Thousand m3 165 142 131 212 210
Rivers Thousand m3 39 37 38 51 59
Others Thousand m3 149 151 154 157 160
Waste
Total Waste Generated t 2,094 2,285 2,338 2,368 2,435
Per unitTotal Waste Generated divided by production volume (unit: hundred million tabletss) - 7.9 7.9 7.6 8.1 8.4
Amount of Waste Recycled t 1,363 1,508 1,323 1,330 1,286
Recycling Rate % 65 66 57 56 53
Amount of Waste Sent to Landfill t 6 3 13 23 18
Waste Plastic Recycling Rate % 82 70 73 70 62
Chemical substances, etc.
Amount of release and transfer of specified chemical substances
Subjects: acetonitrile and methylene chloride (dichloromethane) (before FY2022)
methylene chloride (dichloromethane), xylene, trimethylbenzene, methylnaphthalene (from FY2023 onward)
Clarithromycin added (from FY2024 onward) 		t 31 32 13 15 16
NOx t 20 5 4 13 13
SOx t 0.8 0.6 0.3 0.3 0
Fluorocarbons kt-CO2e - - - - 0.68

* Up to FY2021: Includes only Sawai Pharmaceutical and Kaken Shoyaku (excluding water data and Scope 3 CO2 emissions).
* From FY2022 onward: Includes Trust Pharmatech (excluding water data and Scope 3 GHG emissions).
* From FY2024 onward: Covers the entire Sawai Group.
* From FY2025 onward: Includes energy consumption for vehicle use and fluorocarbon leakage that have received third-party verification.

Social

Status of Employees

Items Units FY2021 FY2022 FY2023 FY2024 FY2025
Number of Employees*1 Persons 2,474 2,944 3,037 3,310 3,630
Manufacturing Persons 1,636 2,015 2,097 2,374 2,662
R&D Persons 253 295 297 300 316
Administration, Sales Persons 585 634 643 636 652
Male Persons 1,663 1,920 1,961 2,150 2,368
Female Persons 811 1,024 1,076 1,160 1,262
Male (Ratio) % 67.2 65.2 64.6 65.0 65.2
Female (Ratio) % 32.8 34.8 35.4 35.0 34.8
Average number of temporary employees Persons 310 328 333 339 372
Number of employees in management positions*1 Persons 256 262 288 325 362
Number of MRs Persons 379 375 376 375 372
Number of persons with pharmacist qualifications*2 Persons 255 246 266 295 299
Average age*3 Years old 38.8 38.2 38.2 39.4 37.3
Male Years old 38.6 38.2 38.3 39.5 37.3
Female Years old 39.0 38.0 37.8 39.4 37.3
Average length of service*3 Years 9.3 8.9 8.6 8.8 8.2
Male Years 9.5 9.2 9 9.2 8.4
Female Years 8.8 8.3 7.7 8.1 7.9
Number of new hires*3 Persons 166 201 242 432 463
Hiring of new graduates Persons 49 83 95 109 214
Male Persons 33 44 58 62 133
Female Persons 16 39 37 47 81
New employees transferred from other company, etc. Persons 117 118 147 323 249
Male Persons 79 82 87 230 182
Female Persons 38 36 60 91 67
Employee turnover rate*3 % 3.3 3.1 4.1 4.0 3.0
Retention of new graduates (at the time after 3years of employment)*4 % 92.9 93.7 94.3 93.4 94.0
Average salary and benefit*5 Million yen 661 722 717 915 985
Percentage of employees covered by collective bargaining agreements*1 % 89.7 91.1 90.5 90.2 90.0
Unionization rate (Sawai Pharmaceutical Workers Union)*1 % 80.5 85.1 86.1 99.2 98.9

*1 Sawai Pharmaceutical, Medisa Shinyaku and Kaken Shoyaku, Trust Pharmatech (from FY2022 onward)
*2 Sawai Pharmaceutical and Kaken Shoyaku, Trust Pharmatech (from FY2022 onward)
*3 Sawai Pharmaceutical only (before FY2022), Sawai Group Domestic Only (FY2023), Entire Sawai Group (from FY2024 onward)
*4 Sawai Pharmaceutical only (before FY2023), Entire Sawai Group (from FY2024 onward)
*5 Sawai Group Holdings only (FY2021)

Diversity Promotion

Items Units FY2021 FY2022 FY2023 FY2024 FY2025
Number of foreign national employees*1 Persons 7 7 8 9 12
Number of female employees in management positions*1 Persons 17 18 24 31 34
Percentage of female employees in management positions*2 % 6.6 6.9 8.3 9.5 9.4
Percentage of disabled employees*3 % 2.38 2.57 2.54 2.79 3.14
Number of employees rehired after retirement*4 Persons 59 78 103 117 135
Percentage of rehired employees who retired at retirement age*4 % 87.5 96.4 81.8 98.3 90.6
Percentage of mid-career employees in management positions*4 % 61.0 63.0 60.9 63.6 65.6

*1 Sawai Pharmaceutical only (before FY2022), Sawai Group Domestic Only (FY2023), Entire Sawai Group (from FY2024 onward)
*2 Sawai Pharmaceutical only (before FY2022), Sawai Group Domestic Only (FY2023), Entire Sawai Group (from FY2024 onward). Target ratio of female employees in managerial positions: 15% and above by the end of March 2027.
*3 Target: To maintain the level over the statutory employment ratio of disabled employees. The statutory employment ratio for disabled employees since April 2025 is 2.7%. The figures are as of June 1 of the following year.
*4 Sawai Pharmaceutical only (before FY2023), Entire Sawai Group (from FY2024 onward)

Work Environment

Items Units FY2021 FY2022 FY2023 FY2024 FY2025
Paid leave utilization rate*1 % 71.1 80.5 78.2 78.3 77.2
Number of employees who take parental leave*2 Persons 42 49 82 100 114
Male Persons 10 20 38 40 70
Female Persons 32 29 44 60 44
Parental leave utilization rate*3 % 34.7 50.0 55.0 67.1 103.4
Return rate from parental leave*4 % 100 100 100 100 100
Number of employees who take family-care leave*5 Persons 0 1 3 0 1
Average hours of overtime work per month*5 Hours 17.7 15.8 15.8 16.8 15.5
Stress check examination rate*4 % 97.6 97.8 98.1 97.5 95.3
Medical checkup rate*4 % 100 100 100 100 100
Smoking rate*4 % 12.8 12.7 11.9 11.7 11.4
Frequency rate of occupational injuries*4 % 0 0.54 0.89 0.66 1.10

*1 Eligible Persons: Union members, Terms: From 1st Jan. to 31st Dec. Sawai Pharmaceutical only (before FY2023), Entire Sawai Group (from FY2024 onward)
*2 Excluding Kaken Shouyaku (before FY2023), Entire Sawai Group (from FY2024 onward)
*3 Denominator is the number of employees who gave birth to children by themselves or their spouses among Sawai-registered or transferred employees to Sawai (from FY2021 to 2023), Entire Sawai Group (from FY2024 onward).
*4 Sawai Pharmaceutical only

Employee Growth

Items Units FY2021 FY2022 FY2023 FY2024 FY2025
Number of employees trained*1 Persons 2,840 4,034 3,795 5,842 8,195
Employee training expenses*2 Million yen 63 88 92 91 112
Pass rate of MR certification test*2 % is not applicable 100 100 100 100

*1 Sawai Group in Japan only (before FY2021), Entire Sawai Group (from FY2024 onward)
*2 Sawai Pharmaceutical, Medisa Shinyaku and Kaken Shoyaku（before FY2021）、Entire Sawai Group (from FY2022 onward).

Products / Stable Supply

Items Units FY2021 FY2022 FY2023 FY2024 FY2025
Number of products*1 Items 790 790 770 750 730
Number of new products launched*2 - 13 generic drugs with 32 strengths 11 generic drugs with 23 strengths 3 generic drugs with 10 strengths 7 generic drugs with 13 strengths 5 generic drugs with 10 strengths
Number of tablets sold*2 Billion tablets 14.8 15.0 15.7 16.1 17.1
Number of patents owned*2 Items 42 45 53 69 78
Number of patents pending*2 Cases 44 32 30 46 62
Number of raw material supplier audits*3 Times 168 212 153 162 124
Number of inquiries to drug information center*2 Cases 49,800 46,700 46,468 45,758 42,661
Number of out of stock products*2 Items 16 6 16 19 11
Product recall (Class Ⅰ)*3 Cases 0 0 0 0 0
Product recall (Class Ⅱ)*3 Cases 8 5 11 8 4
Product recall (Class Ⅲ)*3 Cases 0 0 0 0 0

*1 Sawai Pharmaceutical (The figures are as of April 1 of the following year)
*2 Sawai Pharmaceutical only
*3 Sawai Group in Japan only (before FY2021), Entire Sawai Group (from FY2024 onward)

Promotion of Communication

Items Units FY2021 FY2022 FY2023 FY2024 FY2025
Dialogue with institutional investors and analysts*1 Times 141 154 191 248 182
Communication with the Media*2 Times 42 59 38 27 41
Factory tours Times 12 45 113 85 117
Expenditures for social contribution activities Million yen 212 220 259 98 99

*1 Total
*2 Interview, brief session, etc.

Medical cost-saving impact

Items Units FY2021 FY2022 FY2023 FY2024 FY2025
Medical cost-saving impact Billion yen 338.2 280.9 293.9 220.3 212.9

Governance

Items Units FY2021 FY2022 FY2023 FY2024 FY2025
Number of directors (board members) Persons 6 6 5 5 5
Number of external directors Persons 2 2 3 3 3
Percentage of external directors % 33.3 33.3 60 60 60
Number of female directors Persons 1 1 1 1 1
Percentage of female directors % 16.7 16.7 20.0 20.0 20.0
Number of Audit & Supervisory Board members Persons 3 3 3 3 3
Number of external Audit & Supervisory Board members Persons 2 2 2 2 2
Percentage of external Audit & Supervisory Board members % 66.7 66.7 66.7 66.7 66.7
Number of corporate officers Persons 8 11 8 9 10
Number of female corporate officers Persons 0 1 1 1 1
Number of board meetings Times 13 13 14 14 14
Number of attendances of external directors
Masatoshi Ohara Attendance/Total
%		 13/13
100%		 13/13
100%		 13/14
92.9%		 11/14
78.6%		 14/14
100.0%
Nawomi Todo Attendance/Total
%		 13/13
100%		 13/13
100%		 14/14
100%		 14/14
100%		 3/3
100%
Masayuki Mitsuka Attendance/Total
%		 - - 11/11
100%		 14/14
100%		 14/14
100%
Yasuko Aitoku Attendance/Total
%		 - - - - 11/11
100%
Number of attendances of external Audit & Supervisory Board members
Takanobu Tomohiro Attendance/Total
%		 13/13
100%		 13/13
100%		 14/14
100%		 13/14
92.9%		 2/3
66.7%
Junichi Hirano Attendance/Total
%		 13/13
100%		 13/13
100%		 14/14
100%		 14/14
100%		 3/3
100%
Number of attendances of external Audit & Supervisory Committee Member
Etsuko Taniguchi Attendance/Total
%		 - - - - 11/11
100%
Yukiyo Nose Attendance/Total
%		 - - - - 11/11
100%
Number of Audit & Supervisory Board meetings Times 16 13 13 15 4
Number of attendances of external Audit & Supervisory Board members
Takanobu Tomohiro Attendance/Total
%		 16/16
100%		 13/13
100%		 13/13
100%		 15/15
100%		 4/4
100%
Junichi Hirano Attendance/Total
%		 16/16
100%		 13/13
100%		 13/13
100%		 15/15
100%		 4/4
100%
Number of Audit & Supervisory Committee Times - - - - 11
Number of attendances of external Audit & Supervisory Committee Member
Etsuko Taniguchi Attendance/Total
%		 - - - - 11/11
100%
Yukiyo Nose Attendance/Total
%		 - - - - 11/11
100%
Number of matters to be resolved at the board meeting Cases 77 71 82 71 63
Number of matters to be reported at the board meeting Cases 62 53 74 100 85
Total remuneration allocation for directors (board members) and Audit & Supervisory Board members
Number of eligible directors (excluding Audit & Supervisory Committee Members and external directors) Persons 4 4 5 2 2
Total remuneration allocation Million yen 177 292 118 98 97
Base remuneration Million yen 177 153 77 57 62
Stock options Million yen - 84 15 21 -
Bonuses (Performance-linked) Million yen - 55 26 20 22
Restricted stock remuneration (Continuous service-based) Million yen - - - - 6
Restricted stock remuneration (Performance-linked) Million yen - - - - 7
Number of eligible Audit & Supervisory Board members (excluding external Audit & Supervisory Board members) Persons 1 1 1 1 1
Total remuneration Million yen 17 17 18 18 5
Base remuneration Million yen 17 17 18 18 5
Number of eligible external directors and external Audit & Supervisory Board members Persons 4 4 5 5 8
Total remuneration, etc. Million yen 28 30 42 45 48
Base remuneration Million yen 28 30 42 45 48
Number of days between the dates of dispatch of the convocation notice and annual shareholder’s meeting Days Meeting not held due to the
transformation
into a holding company		 17 18 17 15
Number of cases of whistle-blowing (including consultation) or whistle blowers (Japan) Cases 7 6 7 19 46
Detection by price cartel (Japan) Cases 0 0 0 0 0
Shut down or suspension of business caused by scandal or misconduct (Japan) Cases 0 0 0 0 0
Criminal indictments for accidents or incidents related to compliance violations (Japan) Cases 0 0 0 0 0
Detection by price cartel (Outside Japan) Cases 0 0 0 0 0
Detection by bribery (Outside Japan) Cases 0 0 0 0 0
Detection by other reasons (Outside Japan) Cases 0 0 0 0 0

Back to Sustainability Top